Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)

Review Medicine, General & Internal

Biologic Therapies for Severe Asthma

Guy G. Brusselle et al.

Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Respiratory System

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Simon Couillard et al.

Summary: A risk scale predicting asthma attacks based on blood eosinophil count and exhaled nitric oxide (FeNO) was proposed, showing potential to predict and prevent asthma attacks through anti-inflammatory treatment.

THORAX (2022)

Add to Collection

Editorial Material Respiratory System

Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework

Simon Couillard et al.

RESPIROLOGY (2022)

Add to Collection

Meeting Abstract Respiratory System

Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial)

S. Ramakrishnan et al.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Critical Care Medicine

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

P. Jane McDowell et al.

Summary: This study investigated the inflammatory phenotype and physiological characteristics of exacerbation events in patients with severe eosinophilic asthma treated with mepolizumab. The results showed that exacerbations on mepolizumab could be divided into non-eosinophilic events and eosinophilic events, which could be differentiated using FeNO as a marker. This challenges the routine use of oral corticosteroids for all asthma exacerbation events on mepolizumab, and emphasizes the importance of profiling the inflammatory phenotype for better management.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Meeting Abstract Respiratory System